Deutsche Bank expects Novo Nordisk's ZEUS trial for the drug ziltivekimab to likely fail, with limited potential upside even if successful, due to a looming $30 billion patent cliff in 2031. The trial's outcome is seen as a "sell the news" event, as market expectations are low and the drug's commercial impact would not significantly alter the company's long-term outlook. The key challenge for Novo Nordisk remains developing new blockbuster drugs to offset revenue losses from patent expirations.
The European Commission has approved Novo Nordisk's Wegovy pill, the first oral GLP-1 receptor agonist for weight management across the EU. This approval covers adults with obesity or overweight with related health issues and follows positive clinica...
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
Vivani Medical is developing a semaglutide implant aimed at improving long-term adherence to GLP-1 treatments like Wegovy and Ozempic, which help with obesity and diabetes. The implant, designed to be replaced biannually or annually, could reduce sid...
